Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a New Zealand medical-device company whose products support respiratory care, acute care, neonatal care, and the treatment of obstructive sleep apnea. The company is headquartered in Auckland and sells its products in approximately 120 countries, making it a strongly export-oriented business. Its portfolio includes respiratory humidifiers, breathing circuits, consumable chambers, oxygen-therapy systems, non-invasive ventilation equipment, continuous positive airway pressure equipment, neonatal respiratory products, and related accessories. The business traces its origins to Fisher & Paykel, which began in 1934 as an importer of refrigerators, washing machines, and radios. During the following decades, the wider company moved toward manufacturing and developed its own production and engineering capabilities. A relationship with Kelvinator was established in 1938, while the company’s transition toward products based on internally developed technology accelerated in the mid-1950s. Fisher & Paykel entered healthcare in the late 1960s. The company identified respiratory humidification as an area where its manufacturing and electronics expertise could be applied to an important clinical problem. A New Zealand-developed prototype humidifier for patients receiving ventilation in intensive-care settings was taken into production. This healthcare work became the foundation for a specialized medical-technology business focused on managing the temperature and humidity of gases delivered to patients. Over time, Fisher & Paykel Healthcare expanded beyond hospital humidifiers into complete systems and consumables used with mechanical ventilation, non-invasive ventilation, oxygen therapy, laparoscopic surgery, and neonatal respiratory support. Its sleep-therapy business developed around continuous positive airway pressure treatment for obstructive sleep apnea, including masks, humidification systems, and integrated flow-generator products. The company’s commercial model combines product development, clinical application knowledge, manufacturing, and international distribution. A major corporate restructuring separated the healthcare activities from the appliances and finance businesses in 2001. Fisher & Paykel Industries Limited was renamed Fisher & Paykel Healthcare Corporation Limited, while a newly established Fisher & Paykel Appliances Holdings Limited took ownership of the appliances and finance operations. The healthcare company was listed on the New Zealand and Australian stock exchanges and Nasdaq in connection with the reorganization; its Nasdaq listing ended in February 2003. Manufacturing remains an important part of the company’s identity. Fisher & Paykel Healthcare manufactures, assembles, and tests its product range and many components in New Zealand, supported by additional production in Mexico. A Tijuana facility established in 2010 was reported as producing a substantial share of total volume and serving a significant portion of United States demand by the middle of that decade. A second Tijuana facility was completed in January 2019, and further Mexican capacity was under planning in 2020. The brand is positioned around respiratory-care innovation, clinical utility, integrated systems, and global availability. Rather than being a general medical supplier, it is particularly associated with humidified respiratory therapy and the interfaces, circuits, chambers, and delivery systems that help clinicians and patients receive respiratory support. Its present identity is therefore rooted in the combination of New Zealand engineering, specialized healthcare manufacturing, and international commercialization.

Fisher & Paykel Healthcare traces its origins to Fisher & Paykel, a New Zealand appliance business. In 1969, the parent company began applying engineering capabilities to respiratory humidification. The initial objective was to condition gases delivered to patients receiving mechanical ventilation. This became the foundation of a healthcare business built around the controlled warming and humidification of respiratory gases. The company developed a system-oriented approach. Instead of selling only a humidifier, it designed compatible breathing circuits, water chambers, connectors, and patient interfaces. This approach helped address practical problems such as condensation, infection-control requirements, patient comfort, and reliable delivery of humidified gases. Over time, the portfolio expanded from intensive-care applications into neonatal care, anesthesia, non-invasive ventilation, high-flow nasal therapy, and home treatment for obstructive sleep apnoea. Fisher & Paykel Healthcare established an international presence as respiratory-care technology became increasingly standardized across hospitals and homecare providers. Its products were distributed through direct sales organizations and third-party channels, with regulatory approvals and clinical support required in each market. The company also developed a recurring-revenue component through disposable and replacement products, including circuits, chambers, masks, and other patient-contact or therapy-delivery items. A major corporate turning point came in 2001, when Fisher & Paykel Healthcare was separated from Fisher & Paykel Industries and became an independent listed healthcare company. The demerger allowed the medical-device business to pursue its own research, manufacturing, commercial, and capital-allocation priorities. The company retained the Fisher & Paykel name while building a distinct identity centered on respiratory care. During the 2000s and 2010s, the company broadened its technology platforms and market coverage. Hospital products included humidifiers and circuits for invasive and non-invasive ventilation, while high-flow nasal therapy became a significant clinical category. In homecare, the company developed positive-airway-pressure devices and a range of masks for sleep-apnoea patients. Its brand strategy combined equipment with interfaces and consumables, allowing the company to support a therapy pathway from the respiratory device to the patient. The COVID-19 pandemic was a major operational and commercial episode. Hospitals worldwide increased their need for respiratory support, and demand rose for products used with ventilation and high-flow therapy. Fisher & Paykel Healthcare expanded output and worked through shortages, transport disruption, and changing clinical protocols. The period also increased public awareness of respiratory-care equipment and of the company’s role as a New Zealand medical-device exporter. Today, Fisher & Paykel Healthcare operates as an independent public company with headquarters in Auckland and international sales and support operations. It continues to focus on respiratory products rather than software-based health IT. Its business combines research and development, regulated medical-device manufacturing, clinical education, direct and distributor sales, and a substantial consumables portfolio. The company’s continuing strategic themes are respiratory-care specialization, patient comfort, clinical utility, international expansion, and investment in manufacturing and innovation.

1. 2020COVID-19 increased demand for respiratory products

   The pandemic brought increased global demand for hospital respiratory-care products and led the company to expand production while managing supply-chain pressures.

   Source
2. 2010High-flow respiratory therapy became a major platform

   The company continued commercial development of high-flow nasal therapy products and interfaces for hospital respiratory support.

   Source
3. 2001Healthcare business demerged

   Fisher & Paykel Healthcare became an independent company following its separation from Fisher & Paykel Industries.

   Source
4. 2001Independent public-company era began

   The independent healthcare company continued as a listed New Zealand medical-device business and expanded its international operations.

   Source
5. 1969Respiratory humidification development began

   Fisher & Paykel began developing humidification technology for respiratory-care applications, establishing the technical foundation of the later healthcare business.

   Source

A specialist global respiratory-care medical-device company focused on humidification, patient interfaces, high-flow therapy, sleep-apnoea treatment, and related single-use consumables.

• AirvoHigh-flow respiratory therapy

  Airvo systems deliver warmed and humidified high-flow respiratory gas through a nasal interface. They are used in hospital and other clinical settings for patients who need respiratory support without conventional invasive ventilation. The platform is associated with integrated humidification and ease of setup for high-flow therapy.

• OptiflowNasal high-flow interface

  Optiflow is a family of nasal interfaces designed for delivery of high-flow therapy. The interfaces are used with compatible Fisher & Paykel Healthcare systems and are designed around patient fit, comfort, gas delivery, and clinical usability.

• F&P 950Respiratory humidification

  The F&P 950 is a respiratory humidification system for hospital applications. It is designed to condition gases used in respiratory support and works with associated circuits and consumables. The system reflects the company’s integrated humidifier-and-circuit approach.

• MR850Respiratory humidifier

  The MR850 is a widely used Fisher & Paykel Healthcare humidifier for respiratory support applications. It can be used with compatible breathing circuits and chambers in settings including invasive ventilation, non-invasive ventilation, and other clinical respiratory therapies.

• SleepStylePositive airway pressure

  SleepStyle is the company’s positive-airway-pressure platform for home treatment of obstructive sleep apnoea. It includes therapy equipment and connected or user-facing features intended to support setup, daily use, comfort, and adherence, together with compatible masks and accessories.

• F&P sleep-apnoea masksSleep-apnoea interfaces

  Fisher & Paykel Healthcare produces nasal, nasal-pillow, and full-face interfaces for positive-airway-pressure therapy. Product families have included Evora and Vitera. The masks are designed to provide a seal while addressing fit, facial contact, breathing routes, and patient comfort.

• 2020Increase respiratory-product production during the COVID-19 responseStrategy

  Hospitals faced exceptional demand for respiratory support, including humidification and high-flow therapy products, during the global COVID-19 pandemic.

  What changed. The company increased manufacturing activity and prioritized supply to meet elevated demand while adapting to transport, labor, and component constraints.

  Aftermath. Hospital demand rose materially during the pandemic, and the company continued investing in capacity and supply resilience as demand patterns evolved.

  Source
• 2001Separate the healthcare business from Fisher & Paykel IndustriesStrategy

  The respiratory-care operation had developed into a specialized medical-device business with distinct regulatory, research, manufacturing, and international commercial requirements.

  What changed. Fisher & Paykel Healthcare was demerged from Fisher & Paykel Industries and operated as an independent listed healthcare company.

  Aftermath. The separation enabled the company to focus its corporate strategy and investment on respiratory care, sleep therapy, hospital products, and related consumables.

  Source

• 2021Fisher & Paykel Healthcare reported strong pandemic-era demand for hospital products

  Company reporting described elevated demand for hospital respiratory-care products during the pandemic, alongside continuing investment in manufacturing capacity, research, development, and market infrastructure.

  Other
  Source
• 2020Fisher & Paykel Healthcare expanded respiratory-support production during the COVID-19 pandemic

  The company reported substantially higher demand for hospital respiratory products, including humidification and high-flow therapy equipment, as health systems responded to COVID-19. It increased production and managed significant logistics and supply-chain constraints.

  OtherProduct generation
  Source

1. Fisher & Paykel Healthcare corporate website
2. Fisher & Paykel Healthcare history
3. Fisher & Paykel Healthcare investor information
4. Fisher & Paykel Healthcare hospital respiratory care
5. Fisher & Paykel Healthcare homecare products